{"id":860680,"date":"2025-06-16T07:05:57","date_gmt":"2025-06-16T11:05:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/"},"modified":"2025-06-16T07:05:57","modified_gmt":"2025-06-16T11:05:57","slug":"ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/","title":{"rendered":"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BEDFORD, Mass., June  16, 2025  (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV.<\/p>\n<p>\n        <strong>Clinical Trials at the Summit (CTS) 2025 Presentation Details:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Company Presentation: Ocular Therapeutix<\/strong><br \/>\n          <br \/>Session: Diamond Sponsor Talks<br \/>Presentation Date\/Time:\u00a0Friday, June 20, 2025, 7:55 \u2013 8:05 PM PT<br \/>Presenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Presentation Title: Sustained-Release Axitinib Hydrogel (OTX-TKI) for Wet AMD: US Phase 1 Study Results<\/strong><br \/>\n          <br \/>Session: Tyrosine Kinase Inhibitors in Clinical Trials<br \/>Presentation Date\/Time: Saturday, June 21, 2025, 9:05 \u2013 9:09 AM PT<br \/>Presenter: Patricio G. Schlottmann, MD<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Presentation Title: SOL-1 and SOL-R: Pivotal Phase 3 Trials Evaluating OTX-TKI for Wet AMD<\/strong><br \/>\n          <br \/>Session: Tyrosine Kinase Inhibitors in Clinical Trials<br \/>Presentation Date\/Time: Saturday, June 21, 2025, 9:09 \u2013 9:13 AM PT<br \/>Presenter: Andrea Gibson, PhD, Senior Vice President, Medical Collaborations<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Presentation Title: Safety and Efficacy of OTX-TKI for Diabetic Retinopathy: HELIOS Phase 1 Study<\/strong><br \/>\n          <br \/>Session: Tyrosine Kinase Inhibitors in Clinical Trials<br \/>Presentation Date\/Time: Saturday, June 21, 2025, 9:25 \u2013 9:29 AM PT<br \/>Presenter: Dilsher S. Dhoot, MD<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Panel Title: SOL Program Unpacked: Exploring OTX-TKI\u2019s Potential with Trial Experts<\/strong><br \/>\n          <br \/>Panel Date\/Time: Saturday, June 21, 2025, 9:47 \u2013 10:17 AM PT<br \/>Moderators: Anat Loewenstein, MD, MHA &amp; Daniel F. Martin, MD<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Panel Title: Designing Pivotal Trials Aligned with Evolving Regulatory Guidance<\/strong><br \/>\n          <br \/>Panel Date\/Time: Saturday, June 21, 2025, 12:45 \u2013 1:05 PM PT<br \/>Panelist: Peter K. Kaiser, MD, Chief Development Officer<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Panel Title: Shifting the Landscape: Can Innovation Truly Change the Paradigm?<\/strong><br \/>\n          <br \/>Panel Date\/Time: Saturday, June 21, 2025, 5:25 \u2013 5:45 PM PT<br \/>Moderator: Peter K. Kaiser, MD, Chief Development Officer<\/li>\n<\/ul>\n<p>Exact presentation times may be subject to change.<\/p>\n<p>\n        <strong>About\u00a0Ocular\u00a0Therapeutix,\u00a0Inc.<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI\u2122 (also known as OTX-TKI), Ocular\u2019s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX\u2122 proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).<\/p>\n<p>Ocular\u2019s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA<sup>\u00ae<\/sup>, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA\u2122 (also known as OTX-TIC), which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.<\/p>\n<p>Follow the Company on its website, LinkedIn, or X.<\/p>\n<p>The Ocular Therapeutix logo and DEXTENZA<sup>\u00ae<\/sup>\u00a0are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI\u2122, PAXTRAVA\u2122, ELUTYX\u2122, and Ocular Therapeutix\u2122 are trademarks of Ocular Therapeutix, Inc.<\/p>\n<p>\n        <strong>Investors &amp; Media<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc.<br \/>Bill Slattery<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h-DaLsQC2KvAK3L5PwTd1go0Nt2Vsw2nUihg5I08cxRMBGjkIbQqNTcjAuuZRekgKIygqnhLWY3zfndJ8Z0P5K-ZlpmqvuxWA6T8F6IbajcZpQtcEyKClN_gNPRN_663-2P6rnbwK3mrDEx9pUF1n-nqVTOnVnQTOWiRw-JTXjwqSfw79OUcJhZ3vup3ovn_j0qUZcN5h2_UtFN59yUVb3oaJJkcb4lxDwohgfuKuELEccY5SvyKHYL9ZfwqGrjG9sHEqt-ziJp5hTqQtqAJEA==\" rel=\"nofollow\" target=\"_blank\">bslattery@ocutx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTJlMTNhYTktMGEwNC00Yzg4LTg5YmMtMWI4NjBhNWMxYzljLTEwMjI2MjktMjAyNS0wNi0xNi1lbg==\/tiny\/Ocular-Therapeutix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV. Clinical Trials at the Summit (CTS) 2025 Presentation Details: Company Presentation: Ocular Therapeutix Session: Diamond Sponsor TalksPresentation Date\/Time:\u00a0Friday, June 20, 2025, 7:55 \u2013 8:05 PM PTPresenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer Presentation Title: Sustained-Release Axitinib Hydrogel (OTX-TKI) for Wet AMD: US Phase 1 Study Results Session: Tyrosine Kinase Inhibitors in Clinical TrialsPresentation Date\/Time: Saturday, June 21, 2025, 9:05 \u2013 9:09 AM PTPresenter: Patricio G. Schlottmann, MD Presentation Title: SOL-1 and SOL-R: Pivotal Phase 3 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-860680","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV. Clinical Trials at the Summit (CTS) 2025 Presentation Details: Company Presentation: Ocular Therapeutix Session: Diamond Sponsor TalksPresentation Date\/Time:\u00a0Friday, June 20, 2025, 7:55 \u2013 8:05 PM PTPresenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer Presentation Title: Sustained-Release Axitinib Hydrogel (OTX-TKI) for Wet AMD: US Phase 1 Study Results Session: Tyrosine Kinase Inhibitors in Clinical TrialsPresentation Date\/Time: Saturday, June 21, 2025, 9:05 \u2013 9:09 AM PTPresenter: Patricio G. Schlottmann, MD Presentation Title: SOL-1 and SOL-R: Pivotal Phase 3 &hellip; Continue reading &quot;Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T11:05:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025\",\"datePublished\":\"2025-06-16T11:05:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/\"},\"wordCount\":448,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=\",\"datePublished\":\"2025-06-16T11:05:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025 - Market Newsdesk","og_description":"BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) &#8212; Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV. Clinical Trials at the Summit (CTS) 2025 Presentation Details: Company Presentation: Ocular Therapeutix Session: Diamond Sponsor TalksPresentation Date\/Time:\u00a0Friday, June 20, 2025, 7:55 \u2013 8:05 PM PTPresenter: Sanjay Nayak, MBBS, PhD, Chief Strategy Officer Presentation Title: Sustained-Release Axitinib Hydrogel (OTX-TKI) for Wet AMD: US Phase 1 Study Results Session: Tyrosine Kinase Inhibitors in Clinical TrialsPresentation Date\/Time: Saturday, June 21, 2025, 9:05 \u2013 9:09 AM PTPresenter: Patricio G. Schlottmann, MD Presentation Title: SOL-1 and SOL-R: Pivotal Phase 3 &hellip; Continue reading \"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-16T11:05:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025","datePublished":"2025-06-16T11:05:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/"},"wordCount":448,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/","name":"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=","datePublished":"2025-06-16T11:05:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2ODY4OSM2OTkxMjUwIzIwMTEwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-cts-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Participate in Clinical Trials at the Summit (CTS) 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=860680"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860680\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=860680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=860680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=860680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}